Patients with BRAF-mutated melanoma who have relapsed on or within 6 months of adjuvant BRAFi–MEKi therapy and who have an immediate or absolute contraindication to ICI can be offered the following first-line treatments:. The gene discussed is BRAF; the disease is melanoma.